In Vivo

Proof of Concept "POC" Human Tumor Cell Line-based Xenograft and Syngeneic Models

TD2 has a state of the art 10,000-square-foot, AAALAC-accredited vivarium that is staffed with experts in preclinical oncology research. More than 250 human tumor and murine tumor cell lines, representing all of the major histologies - as well as some rare tumors - are available for compound evaluation. Many lines have been characterized using gene expression profiling data that can guide cell-line selection. In addition to traditional subcutaneous xenograft models, TD2 also offers tumor cell lines as orthotopic and metastatic xenograft models, and can incorporate imaging into these studies with available light-emitting cell lines. In vivo efficacy studies are designed to identify optimal and streamlined development strategies for your experimental agent. Endpoints of studies include tumor growth inhibition (TGI), tumor growth delay (TGD/survival), imaging endpoints, and biomarker analysis.

Imaging Capabilities

TD2’s facility is equipped with a multi-modal AMI 1000 that is designed for powerful bioluminescence, fluorescence and X-ray imaging through collaboration with Spectral Imaging.


TD2 provides strong support for your development programs by offering non-GLP toxicology assessments, including dose range finding, pharmacokinetic analysis, CBC and blood chemistries, and highly sophisticated histopathology services. These data can be extremely valuable in gaining early insights into a drug's activity and toxicity and can be added to any in vivo study as secondary endpoints.

Data Collection and Secure Access

TD2 uses fully integrated, electronic data collection software that allows for more consistent and accurate reporting of data as well as analysis and storage solution for managing research animal studies and processes.

Using Sharefile, our clients have immediate and secure access to their study data. Data is accessible only by unique user name and password assigned at the beginning of a study. Updates are provided on a weekly basis and include individual and group mean tumor volumes, body weights, graphs and observations.